Phase III Results Send VICL Up the Charts
Shares of Vical Inc. (Nasdaq: VICL) were trading up $1.16 (23 percent) to $6.15 per share on volume of 1,341,835. Positive Phase III results announced earlier this morning were the driving force behind VICL’s run up the charts today. The company announced its licensee AnGes MG Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase III trial of an angiogenesis product candidate using VICL's DNA delivery technology. “The successful Phase 3 results from our Japanese licensee position the AnGes product candidate to be the first approved for human use based on…